Innovative Herpes Therapeutics to be Presented in July

Assembly Biosciences, Inc. today announced that the company will present data from its herpes simplex virus (HSV) program at the International Herpesvirus Workshop in Portland, Ore., July 13-17, 2024.

At the Workshop, Assembly Bio will present data describing the preclinical profile of ABI-5366, a long-acting helicase-primase inhibitor candidate in development for treating recurrent genital herpes.

Additionally, the company will present data highlighting the preclinical characterization of ABI-1179, a structurally distinct long-acting helicase-primase inhibitor candidate.

William Delaney, PhD, chief scientific officer of Assembly Bio, commented in a press release on May 22, 2024, "Improved therapeutic options are urgently needed for people living with recurrent genital herpes, as the current standard of care is only partially effective in controlling recurrences."

"Our HSV program employs a highly innovative approach, with candidates designed from the start for long-acting administration and targeting the viral helicase-primase complex, a different viral target than the standard of care."

"We look forward to an important year for the program, as we remain on track to begin dosing in a Phase 1a/1b study for ABI-5366 by mid-year (2024) and anticipate bringing ABI-1179 into the clinic by the end of the year."

Details of the presentations are as follows:

Poster Presentation: The Helicase-Primase Inhibitor ABI-5366 is a Novel, Potent, Long-Acting Inhibitor for the Treatment of Recurrent Genital Herpes
Presenter: Ran Yan, PhD, Assembly Bio
Poster Session Date and Time: Not Yet Available

As of May 23, 2024, there are no U.S. FDA-approved herpes vaccines available.